Cellectar Biosciences INC NEW (CLRB) is a publicly traded Healthcare sector company. As of May 21, 2026, CLRB trades at $3.09 with a market cap of $25.09M and a P/E ratio of -0.38. CLRB moved +3.43% today. Year to date, CLRB is -5.37%; over the trailing twelve months it is -59.97%. Its 52-week range spans $2.43 to $67.50. Analyst consensus is strong buy with an average price target of $10.33. Rallies surfaces CLRB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns CLRB stock?
Hedge funds tracked by Rallies that own CLRB include Two Sigma, Two Sigma, and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cellectar Biosciences INC NEW.
CLRB Key Metrics
Key financial metrics for CLRB
Metric
Value
Price
$3.09
Market Cap
$25.09M
P/E Ratio
-0.38
EPS
$-8.35
Dividend Yield
0.00%
52-Week High
$67.50
52-Week Low
$2.43
Volume
1.64K
Avg Volume
0
Revenue (TTM)
$0
Net Income
$-21.79M
Gross Margin
0.00%
Top Hedge Funds Holding CLRB
Two Sigma holds 71.12K shares of CLRB, changed +251.53% as of Dec 31, 2024.
Two Sigma holds 51.95K shares of CLRB, changed +127.87% as of Dec 31, 2024.
Citadel Advisors holds 9.60K shares of CLRB, changed +3068.32% as of Dec 31, 2024.
Hedge funds tracked by Rallies that own CLRB include Two Sigma, Two Sigma, and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cellectar Biosciences INC NEW.
Does Rallies show 13F holders for CLRB?
Yes. Rallies tracks hedge fund and 13F ownership data for CLRB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CLRB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CLRB. It does not provide personalized investment advice.
